Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

Big Pharma And Five Shining Stars

Posted by Jane Akre
Monday, February 01, 2010 12:41 PM EST
Category: Major Medical
Tags: Big Pharma, Drugmakers, Pharmaceutical Giants, Johnson & Johnson, Amgen, Bayer, Vivus, Novo Nordisk

Five drugs are poised to become blockbusters for the pharmaceutical companies promoting them, if they receive FDA approval.

Drugs That Off Promise of Big Profits



IMAGE SOURCE: money and medicine/ ©iStockphoto

New medications are on the horizon, reports Barrons, and they could mean blockbuster profits for major pharmaceutical companies if the drugs are eventually approved by the Food and Drug Administration.

Expect up to 50 new therapies to win approval this year with the potential to general $15 billion in U.S. sales by 2015.

Drugs to watch for, as they are predicted to generate blockbuster sales include: 

Novo Nordisk – Diabetes drug, Victoza is a daily injectable drug that received FDA approval last week. Also called liraglutide, the drug is a GLP-1 analogue which stimulates insulin production, helping patients lose weight and avoid hypoglycemia. Risks - the drug carries a warning about the risks of thyroid cancer and pancreatitis. Diabetes could double by 2034 due to the aging population.

Dendreon – Prostate cancer therapy, Provenge uses live human cells from the patient cultures with a bioengineered protein found on prostate cancer cells to stimulate the immune system to attack prostate cancer. Risks- Flu-like symptoms were a common side effect.

Vivus – Obesity treatment, Qnexa has helped patients lose an average of 15% of their body mass. Sales could reach more than $1 billion annually. Combining the epilepsy drug, topiramate, with an appetite suppressant, phentermine, (which was considered the safer ingredient in fen-phen). Risks - dull headache and depression, dry mouth, tingling, constipation and insomnia.

Amgen – Osteoporosis drug, Prolia is injected twice yearly and will compete with the bisphosphonate market. FDA should rule by June, reports Barrons. An FDA advisory panel suggests limited uses for the drugs.

Johnson & Johnson and Bayer – Blood thinner, Xarelto, also known as rivaroxaban. Last May, the FDA did not approve the blood thinner, although it is already available in Europe and Canada. It will rival Coumadin, if approved. Xarelto is being tested not only on preventing blood clots, but on atrial fibrillation, and acute coronary syndrome.

Barrons reported a year ago on drug blockbusters of the future, but just three were approved last year. #


Posted by Qnexa
Monday, February 01, 2010 1:12 PM EST

Given that the amounts of each medication in Qnexa have been published (Phentermine and Topiramate) what would prevent a doctor from simply prescribing those drugs in those amounts to be taken by a patient thus eliminating Vivus from collecting any royalties from their trademark. Since these 2 drugs that make up Qnexa are already approved medications.

Posted by Jane Akre
Tuesday, February 02, 2010 10:24 AM EST

Good point. Your news editor wonders why people who want to be healthy are turning to prescription medications when so many of these problems can be cured by the individual with a little guidance and lifestyle change.

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address


RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes